A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib

Publisher： Karger

E-ISSN： 1664-5553|6|3|177-184

ISSN： 2235-1795

Source： Liver Cancer, Vol.6, Iss.3, 2017-03, pp. : 177-184

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma

By  

Liver Cancer, Vol. 5, Iss. 4, 2016-09 ,pp. : 235-244

Karger

Access to resources Recommend Favorite

Systemic Therapies in Hepatocellular Carcinoma

By  

Digestive Diseases, Vol. 27, Iss. 2, 2009-06 ,pp. : 175-188

Karger

Access to resources Recommend Favorite

Systemic Treatment of Hepatocellular Carcinoma

By  

Digestive Diseases, Vol. 19, Iss. 4, 2002-03 ,pp. : 311-323

Karger

Access to resources Recommend Favorite

Gene Therapy of Hepatocellular Carcinoma

By  

Digestive Diseases, Vol. 19, Iss. 4, 2002-03 ,pp. : 324-332

Karger

Access to resources Recommend Favorite

Surgical Therapy of Hepatocellular Carcinoma

By  

Digestion, Vol. 59, Iss. 2, 1998-08 ,pp. : 78-79

Karger

Access to resources Recommend Favorite